The effects of lidocaine on the ventricular fibrillation threshold and primary ventricular fibrillation following acute experimental coronary occlusion

Amiodarone in the new AHA guidelines for ventricular tachyarrhythmias

OBJECTIVE

To delineate amiodarone's role in the new American Heart Association guidelines for ventricular tachyarrhythmias, review the literature that supports the use of amiodarone in ventricular tachyarrhythmias, describe the pharmaceutical properties of amiodarone and elucidate their clinical implications, and discuss the dosing, preparation, and administration of amiodarone.

DATA SOURCES

A search of MEDLINE (1966-October 2000) database and EMBASE Drugs and Pharmacology database (1980-October 2000) was performed. References from published articles and tertiary references were used to gather additional data.

DATA EXTRACTION

All articles were screened, and pertinent studies were identified and evaluated.

DATA SYNTHESIS

Recent trials have demonstrated amiodarone's usefulness in the setting of ventricular tachyarrhythmias. Based on these investigations and contrary to past guidelines, amiodarone is included in the 2000 advanced cardiovascular life support guidelines as a possible agent for hemodynamically stable monomorphic ventricular tachycardia (VT), non-QT prolonged polymorphic VT, and ventricular fibrillation (VF)/pulseless VT. Although not specifically evaluated in the setting of hemodynamically stable monomorphic VT and non-QT prolonged polymorphic VT, investigations by the intravenous Amiodarone Multicenter Trial Group and other clinical trials make amiodarone an acceptable choice for these arrythmia categories. The results of the ARREST (Resuscitation of Refractory Sustained Ventricular Tachyarrhythmias) trial prove amiodarone to be the antiarrhythmic of choice for VF/pulseless VT.

CONCLUSIONS

Amiodarone is classified as a IIb therapeutic intervention for all three arrhythmia categories, which makes it an acceptable, safe, and useful agent with fair to good evidence to support its use. In addition, amiodarone requires careful preparation and delivery to achieve safe and effective outcomes.

The use of antiarrhythmics in advanced cardiac life support

Antiarrhythmic agents have been used to treat malignant ventricular arrhythmias in the setting of acute myocardial ischemia with proven efficacy for many years. Thus, it has been presumed that these agents would be efficacious for the treatment of cardiac arrest. Unfortunately, hard data supporting this contention are unavailable to date. Furthermore, some of the experimental data in this area are conflicting, especially regarding the relative effects of lidocaine and bretylium. Thus, little definitive can be said based on experimental information. In two randomized patient studies, lidocaine and bretylium performed comparably. Because of the frequent use of lidocaine and thus the familiarity of most health care professionals with its use, it makes educational sense to utilize lidocaine as the antiarrhythmic drug of first choice during the cardiac arrest sequence. Recent data suggesting that amiodarone may be efficacious in patients with recurrent arrhythmias require additional confirmation. Although antiarrhythmic agents have been shown to be effective in the treatment of malignant arrhythmias in patients with acute myocardial infarction, their use prophylactically for patients with suspected infarction (advocated in the past) has recently undergone reevaluation. It is now clear that despite a reduction in ventricular fibrillation, overall mortality may be increased. This may be because the prophylactic treatment of patients with suspected infarction includes a large number of patients not at risk for ventricular fibrillation who still may be at risk for drug toxicity. Thus, prophylactic administration of lidocaine to all patients with suspected acute myocardial infarction can no longer be recommended. There are inadequate data upon which to base a recommendation concerning the use of lidocaine in patients receiving thrombolytic therapy. The group most likely to benefit from lidocaine are patients with ST segment elevation who present early after the onset of acute myocardial infarction. The use of lidocaine in this group requires additional study. At present, despite enthusiasm for the prophylactic use of magnesium for the treatment of arrhythmias, data are inadequate to support its routine administration. However, given the importance of magnesium and potassium levels in the genesis of malignant arrhythmias, their levels in plasma should be assessed, and abnormalities should be promptly corrected. The potential uses of antiarrhythmic agents during advanced cardiac life support span a remarkably diverse number of applications. For the purpose of this review, only the use of these agents during CPR and during the early hours of acute or suspected acute myocardial infarction will be considered.

Effect of epinephrine and lidocaine therapy on outcome after cardiac arrest due to ventricular fibrillation

One hundred ninety-nine patients with out-of-hospital cardiac arrest persisted in ventricular fibrillation after the first defibrillation attempt and were then randomly assigned to receive either epinephrine or lidocaine before the next two shocks. The resulting electrocardiographic rhythms and outcomes for each group of patients were compared for each group and also compared with results during the prior 2 years, a period when similar patients primarily received sodium bicarbonate as initial adjunctive therapy. Asystole occurred after defibrillation with threefold frequency after repeated injection of lidocaine (15 of 59, 25%) compared with patients treated with epinephrine (four of 55, 7%) (p less than 0.02). There was no difference in the proportion of patients resuscitated after treatment with either lidocaine or epinephrine (51 of 106, 48% vs. 50 of 93, 54%) and in the proportion surviving (18, 19% vs. 21, 20%), respectively. Resuscitation (64% vs. 50%, p less than 0.005) but not survival rates (24% vs. 20%) were higher during the prior 2-year period in which initial adjunctive drug treatment for persistent ventricular fibrillation primarily consisted of a continuous infusion of sodium bicarbonate. The negative effect of lidocaine or epinephrine treatment was explained in part by their influence on delaying subsequent defibrillation attempts. Survival rates were highest (30%) in a subset of patients who received no drug therapy between shocks. We conclude that currently recommended doses of epinephrine and lidocaine are not useful for improving outcome in patients who persist in ventricular fibrillation.(ABSTRACT TRUNCATED AT 250 WORDS)

The circumflex coronary artery occlusion canine model of sudden death: methodology and electrocardiographic observations

This study deals with a left circumflex coronary artery occlusion-reperfusion canine model of sudden death using multiple electrocardiographic leads to define a subgroup of animals at high risk of ventricular fibrillation. Occlusion was followed by ventricular fibrillation in 15 of 30 animals (50%). In the 15 dogs surviving 60 min postocclusion, reperfusion gave rise to ten cases of ventricular fibrillation (66.7%). Thus, the total incidence of occlusion-reperfusion ventricular fibrillation was 25 of 30 (83.3%). Electrocardiographic delta R% changes greater than or equal to 25% in leads 2 and 3 at both 3 and 5 min postocclusion predicted the occurrence of postocclusion ventricular fibrillation with 80% specificity and 56% sensitivity. However, ST segment elevation greater than or equal to 0.5 mV in the same leads at the same times predicted postocclusion ventricular fibrillation with 67% specificity and 100% sensitivity. When only dogs with ST segment elevation greater than or equal to 0.5 mV in leads 2 and 3 at both 3 and 5 min postocclusion were considered, ventricular fibrillation postocclusion was seen in 15 of 20 dogs (75%) and ventricular fibrillation after reperfusion occurred in four of the remaining five animals (80%). Thus, in the subgroup of animals presenting with ST segment elevation greater than or equal to 0.5 mV in leads 2 and 3 at both 3 and 5 min postocclusion, the overall incidence of occlusion-reperfusion ventricular fibrillation was 19 of 20 (95%). These data may be useful in studies aimed at testing the effectiveness of drugs or other interventions in a canine model of sudden death.

Ventricular fibrillation

Ventricular fibrillation is the most common mechanism of sudden unexpected cardiac death in persons with asymptomatic or symptomatic coronary artery disease. The electrophysiologic mechanisms reviewed in this article include: automaticity of pacemaker fibers, transformation of nonpacemaker into pacemaker fibers, "injury" currents and reentry. Some of the conditions facilitating ventricular fibrillation include bradycardia, long QT syndrome, electrocution, electrolyte imbalance, drugs, sympathetic stimulation and myocardial ischemia. Electrophysiologic studies during acute myocardial ischemia suggest that the earliest activity at the onset of arrhythmia may originate at the sites of the surviving Purkinje fibers or at the epicardial rim. Reentrant arrhythmias arising in ischemic myocardium are attributed to nonhomogeneous distribution of local hyperkalemia and acidosis.